image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.9
12.7 %
$ 11.7 M
Market Cap
1.06
P/E
1. INTRINSIC VALUE

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.[ Read More ]

The intrinsic value of one EGRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.9 USD, Eagle Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EGRX

image
FINANCIALS
317 M REVENUE
84.56%
53.5 M OPERATING INCOME
1935.02%
-2.67 M NET INCOME
-7.48%
30.8 M OPERATING CASH FLOW
-39.26%
0 INVESTING CASH FLOW
100.00%
0 FINANCING CASH FLOW
100.00%
64.6 M REVENUE
-2.50%
10.3 M OPERATING INCOME
66.54%
5.16 M NET INCOME
-10.19%
-126 K OPERATING CASH FLOW
99.62%
-6 K INVESTING CASH FLOW
99.95%
-6.41 M FINANCING CASH FLOW
-50.70%
Balance Sheet Decomposition Eagle Pharmaceuticals, Inc.
image
Current Assets 189 M
Cash & Short-Term Investments 55.3 M
Receivables 73.4 M
Other Current Assets 60 M
Non-Current Assets 217 M
Long-Term Investments 10 M
PP&E 1.17 M
Other Non-Current Assets 206 M
Current Liabilities 111 M
Accounts Payable 19 M
Short-Term Debt 7.78 M
Other Current Liabilities 84.3 M
Non-Current Liabilities 61.5 M
Long-Term Debt 60 M
Other Non-Current Liabilities 1.51 M
EFFICIENCY
Earnings Waterfall Eagle Pharmaceuticals, Inc.
image
Revenue 317 M
Cost Of Revenue 94.9 M
Gross Profit 222 M
Operating Expenses 141 M
Operating Income 53.5 M
Other Expenses 56.1 M
Net Income -2.67 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Eagle Pharmaceuticals, Inc.
image
Net Income -2.67 M
Depreciation & Amortization 16.7 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 866 K
Others -14 M
Free Cash Flow 30.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Eagle Pharmaceuticals, Inc.
image
EGRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Eagle Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Nov 01, 2023
Sell 151 K USD
Tarriff Scott
CEO
- 10925
13.82 USD
1 year ago
Nov 02, 2023
Sell 148 K USD
Tarriff Scott
CEO
- 10694
13.87 USD
1 year ago
Oct 02, 2023
Sell 145 K USD
Tarriff Scott
CEO
- 9511
15.23 USD
1 year ago
Oct 03, 2023
Sell 144 K USD
Tarriff Scott
CEO
- 10024
14.41 USD
1 year ago
Oct 03, 2023
Sell 10.7 K USD
Tarriff Scott
CEO
- 710
15.11 USD
1 year ago
May 16, 2023
Sell 300 K USD
Tarriff Scott
CEO
- 15000
19.98 USD
1 year ago
May 11, 2023
Sell 311 K USD
Tarriff Scott
CEO
- 15000
20.71 USD
1 year ago
May 12, 2023
Sell 61.6 K USD
Tarriff Scott
CEO
- 3131
19.69 USD
1 year ago
May 12, 2023
Sell 242 K USD
Tarriff Scott
CEO
- 11869
20.42 USD
1 year ago
May 15, 2023
Sell 312 K USD
Tarriff Scott
CEO
- 14800
21.06 USD
1 year ago
May 15, 2023
Sell 4.3 K USD
Tarriff Scott
CEO
- 200
21.52 USD
2 years ago
Sep 06, 2022
Sell 211 K USD
Edlin Richard A.
director:
- 6800
30.99 USD
5 years ago
Oct 24, 2019
Sell 93.4 K USD
Hudson Executive Capital LP
Director
- 1494
62.5251 USD
5 years ago
Oct 25, 2019
Sell 981 K USD
Hudson Executive Capital LP
Director
- 15437
63.5682 USD
5 years ago
Oct 21, 2019
Sell 241 K USD
Hudson Executive Capital LP
Director
- 3849
62.5593 USD
5 years ago
Oct 22, 2019
Sell 412 K USD
Hudson Executive Capital LP
Director
- 6567
62.6797 USD
5 years ago
Oct 23, 2019
Sell 12.5 K USD
Hudson Executive Capital LP
Director
- 200
62.58 USD
5 years ago
Oct 16, 2019
Sell 6.38 K USD
Hudson Executive Capital LP
Director
- 102
62.5 USD
5 years ago
Oct 17, 2019
Sell 866 K USD
Hudson Executive Capital LP
Director
- 13842
62.5774 USD
5 years ago
Oct 18, 2019
Sell 100 K USD
Hudson Executive Capital LP
Director
- 1600
62.6088 USD
5 years ago
Oct 10, 2019
Sell 471 K USD
Hudson Executive Capital LP
Director
- 7829
60.1612 USD
5 years ago
Oct 11, 2019
Sell 984 K USD
Hudson Executive Capital LP
Director
- 16300
60.3938 USD
5 years ago
Oct 15, 2019
Sell 245 K USD
Hudson Executive Capital LP
Director
- 3909
62.6339 USD
5 years ago
Oct 07, 2019
Sell 295 K USD
Hudson Executive Capital LP
Director
- 4901
60.1101 USD
5 years ago
Oct 08, 2019
Sell 93.5 K USD
Hudson Executive Capital LP
Director
- 1558
60.0255 USD
5 years ago
Sep 17, 2019
Sell 6 K USD
Hudson Executive Capital LP
Director
- 100
60 USD
5 years ago
Sep 11, 2019
Sell 66.8 K USD
Hudson Executive Capital LP
Director
- 1112
60.0584 USD
5 years ago
Sep 12, 2019
Sell 12 K USD
Hudson Executive Capital LP
Director
- 200
60.07 USD
5 years ago
May 09, 2019
Sell 3.43 M USD
Braunstein Douglas L
Director
- 59223
57.95 USD
5 years ago
May 10, 2019
Sell 5.61 M USD
Braunstein Douglas L
Director
- 100000
56.14 USD
5 years ago
Apr 01, 2019
Sell 1.25 M USD
Tarriff Scott
CEO
- 24975
50.15 USD
5 years ago
Mar 01, 2019
Sell 606 K USD
Tarriff Scott
CEO
- 12000
50.51 USD
5 years ago
Mar 01, 2019
Sell 644 K USD
Tarriff Scott
CEO
- 12428
51.81 USD
5 years ago
Feb 01, 2019
Sell 1.21 M USD
Tarriff Scott
CEO
- 29185
41.52 USD
5 years ago
Feb 01, 2019
Sell 38.1 K USD
Tarriff Scott
CEO
- 900
42.3 USD
5 years ago
Jan 02, 2019
Sell 255 K USD
Tarriff Scott
CEO
- 6500
39.3 USD
5 years ago
Jan 02, 2019
Sell 340 K USD
Tarriff Scott
CEO
- 8500
40.03 USD
5 years ago
Jan 03, 2019
Sell 414 K USD
Tarriff Scott
CEO
- 10597
39.04 USD
5 years ago
Jan 03, 2019
Sell 225 K USD
Tarriff Scott
CEO
- 5670
39.7 USD
5 years ago
Jan 03, 2019
Sell 12.3 K USD
Tarriff Scott
CEO
- 302
40.57 USD
6 years ago
Mar 06, 2018
Sell 126 K USD
FLAUM SANDER A
Director
- 2340
53.94 USD
7 years ago
Aug 16, 2017
Bought 19.4 K USD
Meyers Pete A.
Chief Financial Officer
+ 350
55.4468 USD
7 years ago
Aug 09, 2017
Bought 79.3 K USD
Braunstein Douglas L
Director
+ 1584
50.0874 USD
7 years ago
Aug 09, 2017
Bought 748 K USD
Braunstein Douglas L
Director
+ 15206
49.2081 USD
7 years ago
Aug 09, 2017
Bought 173 K USD
Braunstein Douglas L
Director
+ 3610
48.0581 USD
7 years ago
Jun 12, 2017
Bought 25 K USD
Meyers Pete A.
Chief Financial Officer
+ 350
71.4879 USD
7 years ago
May 19, 2017
Bought 20.3 K USD
Pernock David
Pres. & Chief Comm. Officer
+ 255
79.69 USD
7 years ago
May 16, 2017
Bought 16.4 K USD
Pernock David
Pres. & Chief Comm. Officer
+ 200
82.24 USD
7 years ago
Apr 25, 2017
Sell 4.52 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 51219
88.34 USD
7 years ago
Apr 25, 2017
Sell 264 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 2961
89.09 USD
7 years ago
Mar 30, 2017
Sell 517 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 6223
83 USD
7 years ago
Mar 31, 2017
Sell 1.97 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 23689
83.02 USD
7 years ago
Apr 03, 2017
Sell 5.11 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 61420
83.13 USD
7 years ago
Mar 27, 2017
Sell 3.13 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 37731
83 USD
7 years ago
Mar 28, 2017
Sell 513 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 6182
83.02 USD
7 years ago
Mar 29, 2017
Sell 4.88 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 58755
83.01 USD
7 years ago
Mar 27, 2017
Sell 108 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1300
83 USD
7 years ago
Mar 29, 2017
Sell 133 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1600
83.01 USD
7 years ago
Mar 27, 2017
Sell 33.2 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 400
83 USD
7 years ago
Mar 29, 2017
Sell 41.5 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 500
83.01 USD
7 years ago
Mar 23, 2017
Sell 576 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 7025
82.0625 USD
7 years ago
Mar 22, 2017
Sell 569 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 7100
80.0903 USD
7 years ago
Mar 21, 2017
Sell 41.6 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 500
83.1 USD
7 years ago
Mar 23, 2017
Sell 58.1 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 700
83.01 USD
7 years ago
Mar 22, 2017
Bought 477 K USD
Edlin Richard A.
Director
+ 6000
79.44 USD
7 years ago
Mar 21, 2017
Bought 5.12 K USD
Pernock David
Pres. & Chief Comm. Officer
+ 61
83.98 USD
7 years ago
Mar 16, 2017
Sell 749 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 9120
82.08 USD
7 years ago
Mar 17, 2017
Sell 3.2 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 38997
82.01 USD
7 years ago
Mar 20, 2017
Sell 4.26 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 51883
82.1 USD
7 years ago
Mar 09, 2017
Bought 35 K USD
Pernock David
Pres. & Chief Comm. Officer
+ 450
77.8411 USD
7 years ago
Jan 04, 2017
Sell 5.55 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 65114
85.16 USD
7 years ago
Dec 21, 2016
Sell 584 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 7569
77.1747 USD
7 years ago
Dec 23, 2016
Sell 403 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 5127
78.6069 USD
7 years ago
Dec 19, 2016
Sell 553 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 7317
75.6066 USD
7 years ago
Dec 15, 2016
Sell 469 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 6270
74.7896 USD
7 years ago
Dec 20, 2016
Sell 767 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 10000
76.6876 USD
7 years ago
Dec 22, 2016
Sell 394 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 5126
76.7794 USD
7 years ago
Dec 13, 2016
Sell 736 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 10000
73.6163 USD
10 years ago
Apr 03, 2014
Bought 50.5 K USD
RATOFF STEVEN B
Director
+ 3950
12.79 USD
7 years ago
Dec 12, 2016
Sell 97.6 K USD
RATOFF STEVEN B
Director
- 1300
75.07 USD
7 years ago
Dec 13, 2016
Sell 652 K USD
RATOFF STEVEN B
Director
- 8700
75 USD
7 years ago
Nov 30, 2016
Sell 105 K USD
Krill Steven L.
EVP & Chief Scientific Officer
- 1307
80 USD
7 years ago
Nov 28, 2016
Sell 393 K USD
FLAUM SANDER A
Director
- 5000
78.66 USD
8 years ago
Nov 10, 2016
Sell 1.31 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 15368
85.1 USD
8 years ago
Nov 10, 2016
Sell 14.4 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 167
86 USD
8 years ago
Nov 10, 2016
Sell 8.61 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 100
86.06 USD
8 years ago
Nov 10, 2016
Sell 148 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1700
87.05 USD
8 years ago
Nov 11, 2016
Sell 1.32 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 15551
85 USD
8 years ago
Nov 10, 2016
Sell 110 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1300
85 USD
8 years ago
Nov 10, 2016
Sell 25.5 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 300
85 USD
8 years ago
Nov 07, 2016
Sell 379 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 5030
75.39 USD
8 years ago
Nov 09, 2016
Sell 104 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1380
75.7 USD
8 years ago
Nov 09, 2016
Sell 894 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 11690
76.49 USD
8 years ago
Nov 09, 2016
Sell 696 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 9030
77.13 USD
8 years ago
Nov 09, 2016
Sell 329 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 4200
78.23 USD
8 years ago
Nov 09, 2016
Sell 1.55 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 19581
79.24 USD
8 years ago
Nov 09, 2016
Sell 8.24 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 102919
80.09 USD
8 years ago
Nov 02, 2016
Sell 10.2 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 146371
70 USD
8 years ago
Nov 04, 2016
Sell 3.46 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 46170
75 USD
8 years ago
Nov 02, 2016
Sell 3.54 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 50329
70.41 USD
8 years ago
Nov 02, 2016
Sell 147 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 2100
70 USD
8 years ago
Nov 02, 2016
Sell 56 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 800
70 USD
8 years ago
Sep 30, 2016
Sell 1.55 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 22100
70.06 USD
8 years ago
Sep 29, 2016
Sell 5.46 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 77900
70.04 USD
8 years ago
Sep 21, 2016
Sell 6.43 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 97149
66.15 USD
8 years ago
Sep 21, 2016
Sell 121 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 1798
67.24 USD
8 years ago
Sep 21, 2016
Sell 43.3 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 654
66.17 USD
8 years ago
Sep 21, 2016
Sell 12.8 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 194
66.17 USD
8 years ago
Sep 06, 2016
Sell 809 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 12958
62.45 USD
8 years ago
Sep 06, 2016
Sell 773 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 12224
63.25 USD
8 years ago
Sep 07, 2016
Sell 706 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 11345
62.26 USD
8 years ago
Sep 08, 2016
Sell 2.11 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 33796
62.33 USD
8 years ago
Sep 06, 2016
Sell 10.4 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 166
62.83 USD
8 years ago
Sep 07, 2016
Sell 4.67 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 75
62.26 USD
8 years ago
Sep 08, 2016
Sell 14 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 224
62.33 USD
8 years ago
Sep 06, 2016
Sell 3.08 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 49
62.83 USD
8 years ago
Sep 07, 2016
Sell 1.37 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 22
62.26 USD
8 years ago
Sep 08, 2016
Sell 4.11 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 66
62.33 USD
8 years ago
Aug 23, 2016
Sell 1.08 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 17118
63.14 USD
8 years ago
Aug 24, 2016
Sell 722 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 11506
62.78 USD
8 years ago
Aug 23, 2016
Sell 7.13 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 113
63.12 USD
8 years ago
Aug 24, 2016
Sell 4.77 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 76
62.78 USD
8 years ago
Aug 23, 2016
Sell 2.15 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 34
63.12 USD
8 years ago
Aug 24, 2016
Sell 1.44 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 23
62.78 USD
8 years ago
Aug 15, 2016
Sell 1.01 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 16667
60.51 USD
8 years ago
Aug 15, 2016
Sell 495 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 8070
61.31 USD
8 years ago
Aug 16, 2016
Sell 987 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 16270
60.66 USD
8 years ago
Aug 16, 2016
Sell 726 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 11770
61.65 USD
8 years ago
Aug 16, 2016
Sell 1.97 M USD
ProQuest Investments IV, L.P.
10 percent owner
- 31599
62.21 USD
8 years ago
Aug 17, 2016
Sell 287 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 4723
60.85 USD
8 years ago
Aug 17, 2016
Sell 603 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 9848
61.19 USD
8 years ago
Aug 15, 2016
Sell 9.89 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 163
60.7 USD
8 years ago
Aug 16, 2016
Sell 23.9 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 394
60.78 USD
8 years ago
Aug 17, 2016
Sell 5.86 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 96
61 USD
8 years ago
Aug 15, 2016
Sell 2.97 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 49
60.7 USD
8 years ago
Aug 16, 2016
Sell 7.11 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 117
60.78 USD
8 years ago
Aug 17, 2016
Sell 1.77 K USD
ProQuest Investments IV, L.P.
10 percent owner
- 29
61 USD
8 years ago
May 12, 2016
Sell 160 K USD
ProQuest Management LLC
10 percent owner
- 4000
40 USD
8 years ago
May 13, 2016
Sell 572 K USD
ProQuest Management LLC
10 percent owner
- 13980
40.92 USD
8 years ago
Apr 01, 2016
Sell 1.25 M USD
Tarriff Scott
President and CEO
- 30765
40.63 USD
8 years ago
Mar 15, 2016
Bought 56.7 K USD
Graves Michael
Director
+ 1000
56.73 USD
8 years ago
Mar 01, 2016
Sell 489 K USD
Tarriff Scott
President and CEO
- 7802
62.7 USD
8 years ago
Mar 01, 2016
Sell 761 K USD
Tarriff Scott
President and CEO
- 11978
63.52 USD
8 years ago
Feb 01, 2016
Sell 354 K USD
Tarriff Scott
President and CEO
- 5367
66.03 USD
8 years ago
Feb 01, 2016
Sell 243 K USD
Tarriff Scott
President and CEO
- 3600
67.46 USD
8 years ago
Feb 01, 2016
Sell 360 K USD
Tarriff Scott
President and CEO
- 5260
68.52 USD
8 years ago
Feb 01, 2016
Sell 170 K USD
Tarriff Scott
President and CEO
- 2431
69.95 USD
8 years ago
Feb 01, 2016
Sell 122 K USD
Tarriff Scott
President and CEO
- 1702
71.84 USD
8 years ago
Jan 04, 2016
Sell 1.01 M USD
Tarriff Scott
President and CEO
- 11776
85.65 USD
8 years ago
Jan 04, 2016
Sell 241 K USD
Tarriff Scott
President and CEO
- 2773
87.02 USD
9 years ago
Mar 20, 2015
Sell 412 K USD
FLAUM SANDER A
Director
- 9800
42 USD
8 years ago
Dec 22, 2015
Sell 302 K USD
FLAUM SANDER A
Director
- 3225
93.755 USD
8 years ago
Dec 01, 2015
Sell 244 K USD
Tarriff Scott
President and CEO
- 2806
86.92 USD
8 years ago
Dec 01, 2015
Sell 417 K USD
Tarriff Scott
President and CEO
- 4744
87.85 USD
8 years ago
Dec 01, 2015
Sell 133 K USD
Tarriff Scott
President and CEO
- 1500
88.8 USD
8 years ago
Dec 01, 2015
Sell 337 K USD
Tarriff Scott
President and CEO
- 3700
90.99 USD
8 years ago
Dec 01, 2015
Sell 119 K USD
Tarriff Scott
President and CEO
- 1300
91.46 USD
9 years ago
Nov 02, 2015
Sell 750 K USD
Tarriff Scott
President and CEO
- 11713
64.07 USD
9 years ago
Nov 02, 2015
Sell 500 K USD
Tarriff Scott
President and CEO
- 7626
65.5 USD
9 years ago
Oct 01, 2015
Sell 223 USD
Tarriff Scott
President and CEO
- 3
74.355 USD
9 years ago
Oct 01, 2015
Sell 112 K USD
Tarriff Scott
President and CEO
- 1548
72.67 USD
9 years ago
Oct 01, 2015
Sell 494 K USD
Tarriff Scott
President and CEO
- 7027
70.28 USD
9 years ago
Oct 01, 2015
Sell 570 K USD
Tarriff Scott
President and CEO
- 8235
69.27 USD
9 years ago
Oct 01, 2015
Sell 73 K USD
Tarriff Scott
President and CEO
- 1065
68.5 USD
9 years ago
Sep 01, 2015
Sell 197 K USD
Tarriff Scott
President and CEO
- 2526
77.93 USD
9 years ago
Sep 01, 2015
Sell 907 K USD
Tarriff Scott
President and CEO
- 11792
76.88 USD
9 years ago
Sep 01, 2015
Sell 143 K USD
Tarriff Scott
President and CEO
- 1878
76.09 USD
9 years ago
Sep 01, 2015
Sell 3.68 K USD
Tarriff Scott
President and CEO
- 49
75.12 USD
9 years ago
Aug 03, 2015
Sell 1.03 M USD
Tarriff Scott
President and CEO
- 10658
96.36 USD
9 years ago
Aug 03, 2015
Sell 223 K USD
Tarriff Scott
President and CEO
- 2342
95.39 USD
9 years ago
Mar 20, 2015
Sell 5.04 M USD
Tarriff Scott
President and CEO
- 120000
42 USD
9 years ago
Jul 01, 2015
Sell 367 K USD
Tarriff Scott
President and CEO
- 4502
81.5 USD
9 years ago
Jul 01, 2015
Sell 119 K USD
Tarriff Scott
President and CEO
- 1483
80.28 USD
9 years ago
Jul 01, 2015
Sell 475 K USD
Tarriff Scott
President and CEO
- 6015
78.98 USD
9 years ago
Jul 01, 2015
Sell 288 K USD
Tarriff Scott
President and CEO
- 3710
77.58 USD
9 years ago
Jun 16, 2015
Sell 114 K USD
Krill Steven L.
Chief Scientific Officer
- 1400
81.6 USD
10 years ago
Feb 18, 2014
Bought 5 M USD
SCHREIBER ALAIN
director, 10 percent owner:
+ 333333
15 USD
10 years ago
Feb 18, 2014
Bought 5 M USD
Moorin Jay
director, 10 percent owner:
+ 333333
15 USD
10 years ago
Feb 18, 2014
Bought 5 M USD
ProQuest Associates IV LLC
10 percent owner
+ 333333
15 USD
7. News
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the “SEC”) to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC. globenewswire.com - 1 day ago
INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders. accesswire.com - 3 weeks ago
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX, Financial). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share. gurufocus.com - 1 month ago
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an additional and separate basis for delisting. globenewswire.com - 2 months ago
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has initiated a process to delist the Company's securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 (the “Q3 2023 Form 10-Q”) and its Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) by May 13, 2024. The Notice further advises the Company that, pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) serves as an additional and separate basis for delisting. globenewswire.com - 5 months ago
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- globenewswire.com - 7 months ago
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. globenewswire.com - 7 months ago
Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 9 months ago
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX. prnewswire.com - 9 months ago
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66572&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 9 months ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66547&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 9 months ago
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. prnewswire.com - 9 months ago
8. Profile Summary

Eagle Pharmaceuticals, Inc. EGRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 11.7 M
Dividend Yield 0.00%
Description Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Contact 50 Tice Boulevard, Woodcliff Lake, NJ, 07677 https://www.eagleus.com
IPO Date Feb. 12, 2014
Employees 134
Officers Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board